153 related articles for article (PubMed ID: 9925308)
1. Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir.
Kim DK; Lee N; Im GJ; Kim HT; Kim KH
Bioorg Med Chem; 1998 Dec; 6(12):2525-30. PubMed ID: 9925308
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of 2-amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine mono- and diesters as potential prodrugs of penciclovir.
Kim DK; Lee N; Kim HT; Im GJ; Kim KH
Bioorg Med Chem; 1999 Mar; 7(3):565-70. PubMed ID: 10220040
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 2-amino-9-(1, 3-dihydroxy-2-propoxymethyl)- 6-fluoropurine mono- and diesters as potential prodrugs of ganciclovir.
Kim DK; Chang K; Im GJ; Kim HT; Lee N; Kim KH
J Med Chem; 1999 Jan; 42(2):324-8. PubMed ID: 9925738
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
Kim DK; Lee N; Kim YW; Chang K; Kim JS; Im GJ; Choi WS; Jung I; Kim TS; Hwang YY; Min DS; Um KA; Cho YB; Kim KH
J Med Chem; 1998 Aug; 41(18):3435-41. PubMed ID: 9719596
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
6. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.
Smiley ML; Murray A; de Miranda P
Adv Exp Med Biol; 1996; 394():33-9. PubMed ID: 8815698
[No Abstract] [Full Text] [Related]
7. Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1- yl)purines as potential prodrugs of penciclovir.
Kim DK; Lee N; Ryu DH; Kim YW; Kim JS; Chang K; Im GJ; Choi WS; Cho YB; Kim KH; Colledge D; Locarnini S
Bioorg Med Chem; 1999 Aug; 7(8):1715-25. PubMed ID: 10482463
[TBL] [Abstract][Full Text] [Related]
8. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.
Anand BS; Hill JM; Dey S; Maruyama K; Bhattacharjee PS; Myles ME; Nashed YE; Mitra AK
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2529-34. PubMed ID: 12766053
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of new antiherpes agents: famciclovir and valacyclovir.
Stein GE
J Am Pharm Assoc (Wash); 1997; NS37(2):157-63. PubMed ID: 9069689
[TBL] [Abstract][Full Text] [Related]
10. Syntheses, chemical and enzymatic stability of new poly(ethylene glycol)-acyclovir prodrugs.
Zacchigna M; Di Luca G; Maurich V; Boccù E
Farmaco; 2002 Mar; 57(3):207-14. PubMed ID: 11989799
[TBL] [Abstract][Full Text] [Related]
11. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice.
LeBlanc RA; Pesnicak L; Godleski M; Straus SE
J Infect Dis; 1999 Sep; 180(3):594-9. PubMed ID: 10438344
[TBL] [Abstract][Full Text] [Related]
12. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.
Purifoy DJ; Beauchamp LM; de Miranda P; Ertl P; Lacey S; Roberts G; Rahim SG; Darby G; Krenitsky TA; Powell KL
J Med Virol; 1993; Suppl 1():139-45. PubMed ID: 8245881
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
Beutner KR
Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model.
Field HJ; Tewari D; Sutton D; Thackray AM
Antimicrob Agents Chemother; 1995 May; 39(5):1114-9. PubMed ID: 7625798
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of amino acid esters of 6-deoxypenciclovir as potential prodrugs of penciclovir.
Kim DK; Lee N; Kim YW; Chang K; Im GJ; Choi WS; Kim KH
Bioorg Med Chem; 1999 Feb; 7(2):419-24. PubMed ID: 10218837
[TBL] [Abstract][Full Text] [Related]
17. Successful kinase bypass with new acyclovir phosphoramidate prodrugs.
McGuigan C; Derudas M; Bugert JJ; Andrei G; Snoeck R; Balzarini J
Bioorg Med Chem Lett; 2008 Aug; 18(15):4364-7. PubMed ID: 18614365
[TBL] [Abstract][Full Text] [Related]
18. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.
Kim I; Song X; Vig BS; Mittal S; Shin HC; Lorenzi PJ; Amidon GL
Mol Pharm; 2004; 1(2):117-27. PubMed ID: 15832508
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells.
Friedrichsen GM; Chen W; Begtrup M; Lee CP; Smith PL; Borchardt RT
Eur J Pharm Sci; 2002 Jul; 16(1-2):1-13. PubMed ID: 12113886
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
Eksborg S; Pal N; Kalin M; Palm C; Söderhäll S
Med Pediatr Oncol; 2002 Apr; 38(4):240-6. PubMed ID: 11920787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
